SK19052000A3 - Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch - Google Patents

Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch Download PDF

Info

Publication number: SK19052000A3
Authority: SK; Slovakia
Prior art keywords: norcisapride; administered; pharmaceutically acceptable; stereoisomer; apnea
Prior art date: 1998-06-15

Application number

SK1905-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Paul D. Rubin

Timothy J. Barberich

Original Assignee

Sepracor, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-15

Filing date

1999-06-10

Publication date

2001-06-11

1999-06-10 Application filed by Sepracor, Inc. filed Critical Sepracor, Inc.

2001-06-11 Publication of SK19052000A3 publication Critical patent/SK19052000A3/sk

Links

ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 title claims abstract description 103
208000008784 apnea Diseases 0.000 title claims abstract description 54
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 40
206010006550 Bulimia nervosa Diseases 0.000 title claims abstract description 28
208000032841 Bulimia Diseases 0.000 title claims description 24
150000003839 salts Chemical class 0.000 claims abstract description 46
238000011282 treatment Methods 0.000 claims abstract description 39
208000035475 disorder Diseases 0.000 claims abstract description 33
208000006218 bradycardia Diseases 0.000 claims abstract description 27
230000002265 prevention Effects 0.000 claims abstract description 16
206010046543 Urinary incontinence Diseases 0.000 claims abstract description 14
230000036471 bradycardia Effects 0.000 claims abstract description 14
208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 14
206010049765 Bradyarrhythmia Diseases 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 26
208000006673 asthma Diseases 0.000 claims description 18
239000002775 capsule Substances 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 18
241000124008 Mammalia Species 0.000 claims description 16
241000282414 Homo sapiens Species 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 11
230000000414 obstructive effect Effects 0.000 claims description 6
201000002859 sleep apnea Diseases 0.000 claims description 6
208000003417 Central Sleep Apnea Diseases 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
230000009747 swallowing Effects 0.000 claims description 3
238000000034 method Methods 0.000 abstract description 32
206010042772 syncope Diseases 0.000 abstract description 30
208000024891 symptom Diseases 0.000 abstract description 19
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 36
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 36
229960005132 cisapride Drugs 0.000 description 32
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 31
239000000203 mixture Substances 0.000 description 30
239000004480 active ingredient Substances 0.000 description 27
150000001875 compounds Chemical class 0.000 description 22
OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 description 17
229940079593 drug Drugs 0.000 description 16
239000003826 tablet Substances 0.000 description 16
210000004027 cell Anatomy 0.000 description 14
238000009472 formulation Methods 0.000 description 14
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
238000013270 controlled release Methods 0.000 description 12
239000003446 ligand Substances 0.000 description 12
239000002552 dosage form Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
230000027455 binding Effects 0.000 description 10
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
230000004044 response Effects 0.000 description 9
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
210000001186 vagus nerve Anatomy 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000002354 daily effect Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000008187 granular material Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 5
206010047700 Vomiting Diseases 0.000 description 5
239000000556 agonist Substances 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000000835 fiber Substances 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000029058 respiratory gaseous exchange Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
208000004557 Vasovagal Syncope Diseases 0.000 description 4
150000003936 benzamides Chemical class 0.000 description 4
102000005936 beta-Galactosidase Human genes 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
229940076279 serotonin Drugs 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010041235 Snoring Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
206010003119 arrhythmia Diseases 0.000 description 3
238000003556 assay Methods 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000007891 compressed tablet Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000003825 pressing Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 2
108091005479 5-HT2 receptors Proteins 0.000 description 2
102000035037 5-HT3 receptors Human genes 0.000 description 2
108091005477 5-HT3 receptors Proteins 0.000 description 2
108091005482 5-HT4 receptors Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
206010050202 Carotid sinus syndrome Diseases 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241000134128 Syncope Species 0.000 description 2
208000018452 Torsade de pointes Diseases 0.000 description 2
208000002363 Torsades de Pointes Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000621 bronchi Anatomy 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
235000017471 coenzyme Q10 Nutrition 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000003979 granulating agent Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
208000001797 obstructive sleep apnea Diseases 0.000 description 2
239000003921 oil Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229960001416 pilocarpine Drugs 0.000 description 2
-1 pilocarpine compound Chemical class 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000003334 potential effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
229960004747 ubidecarenone Drugs 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
208000003663 ventricular fibrillation Diseases 0.000 description 2
206010047302 ventricular tachycardia Diseases 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
DCSUBABJRXZOMT-RBBKRZOGSA-N 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide Chemical compound C([C@H]([C@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-RBBKRZOGSA-N 0.000 description 1
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010038669 Respiratory arrest Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000002210 biocatalytic effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000008344 brain blood flow Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000011128 cardiac conduction Effects 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
210000001326 carotid sinus Anatomy 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000028925 conduction system disease Diseases 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960001271 desloratadine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
235000005686 eating Nutrition 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002322 enterochromaffin cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
239000010445 mica Substances 0.000 description 1
229910052618 mica group Inorganic materials 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000008035 nerve activity Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
OMLDMGPCWMBPAN-UHFFFAOYSA-N norcisapride Chemical compound COC1CNCCC1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-UHFFFAOYSA-N 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
229960001687 orphenadrine citrate Drugs 0.000 description 1
MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 description 1
230000002746 orthostatic effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
229960002393 primidone Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001034 respiratory center Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000003019 respiratory muscle Anatomy 0.000 description 1
210000004767 rumen Anatomy 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
229940121356 serotonin receptor antagonist Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007905 soft elastic gelatin capsule Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1905-2000A 1998-06-15 1999-06-10 Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch SK19052000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8922498P	1998-06-15	1998-06-15
US12227599P	1999-03-01	1999-03-01
PCT/US1999/013099 WO1999065571A2 (en)	1998-06-15	1999-06-10	Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders

Publications (1)

Publication Number	Publication Date
SK19052000A3 true SK19052000A3 (sk)	2001-06-11

Family

ID=26780365

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1905-2000A SK19052000A3 (sk)	1998-06-15	1999-06-10	Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch

Country Status (26)

Country	Link
US (4)	US6048879A (cs)
EP (1)	EP1089733B1 (cs)
JP (1)	JP2002518352A (cs)
KR (3)	KR20010052739A (cs)
CN (1)	CN1312717A (cs)
AR (1)	AR019671A1 (cs)
AT (1)	ATE291427T1 (cs)
AU (1)	AU4433399A (cs)
BG (1)	BG105096A (cs)
BR (1)	BR9911299A (cs)
CA (1)	CA2333666A1 (cs)
CZ (1)	CZ20004737A3 (cs)
DE (1)	DE69924375T2 (cs)
ES (1)	ES2237110T3 (cs)
HK (1)	HK1040058A1 (cs)
HU (1)	HUP0102203A3 (cs)
IL (1)	IL140118A0 (cs)
IS (1)	IS5756A (cs)
NO (1)	NO20006357L (cs)
NZ (3)	NZ535135A (cs)
PL (1)	PL345275A1 (cs)
PT (1)	PT1089733E (cs)
SI (1)	SI1089733T1 (cs)
SK (1)	SK19052000A3 (cs)
TR (7)	TR200103057T2 (cs)
WO (1)	WO1999065571A2 (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060241164A1 (en) *	1998-02-27	2006-10-26	The Board Of Trustees Of The University Of Illinoi	Pharmacological treatment for sleep apnea
US7160898B2 (en) *	2001-12-14	2007-01-09	Board Of Trustees Of The University Of Illinois	Pharmacological treatment for sleep apnea
JP2003522103A (ja)	1998-06-15	2003-07-22	セプラコアインコーポレーテッド	無呼吸、過食症およびその他の障害を治療するための光学的に純粋な（−）−ノルシスアプリドの使用
EP1435238A1 (en) *	1999-03-01	2004-07-07	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
US6548082B1 (en) *	1999-03-01	2003-04-15	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6353005B1 (en) *	1999-03-02	2002-03-05	Sepracor, Inc.	Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2817619A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7613515B2 (en) *	2003-02-03	2009-11-03	Enteromedics Inc.	High frequency vagal blockage therapy
US7844338B2 (en)	2003-02-03	2010-11-30	Enteromedics Inc.	High frequency obesity treatment
US7444183B2 (en) *	2003-02-03	2008-10-28	Enteromedics, Inc.	Intraluminal electrode apparatus and method
US20040172084A1 (en)	2003-02-03	2004-09-02	Knudson Mark B.	Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US20050070970A1 (en) *	2003-09-29	2005-03-31	Knudson Mark B.	Movement disorder stimulation with neural block
US20050070974A1 (en) *	2003-09-29	2005-03-31	Knudson Mark B.	Obesity and eating disorder stimulation treatment with neural block
WO2005120363A1 (en)	2004-06-03	2005-12-22	Mayo Foundation For Medical Education And Research	Obesity treatment and device
US20060020298A1 (en) *	2004-07-20	2006-01-26	Camilleri Michael L	Systems and methods for curbing appetite
US20060020277A1 (en) *	2004-07-20	2006-01-26	Gostout Christopher J	Gastric reshaping devices and methods
US7833279B2 (en) *	2004-11-12	2010-11-16	Enteromedics Inc.	Pancreatic exocrine secretion diversion apparatus and method
CN101132777A (zh)	2004-12-20	2008-02-27	科利吉姆制药公司	用于睡眠障碍的药物组合物
US7822486B2 (en) *	2005-08-17	2010-10-26	Enteromedics Inc.	Custom sized neural electrodes
US7672727B2 (en) *	2005-08-17	2010-03-02	Enteromedics Inc.	Neural electrode treatment
GB0524668D0 (en) *	2005-12-02	2006-01-11	Novartis Ag	Organic compounds
WO2007098200A2 (en)	2006-02-16	2007-08-30	Imthera Medical, Inc.	An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea
EP2197536A1 (en)	2007-10-09	2010-06-23	Imthera Medical, Inc.	System and method for neural stimulation
BRPI0920548B8 (pt)	2008-10-09	2021-06-22	Imthera Medical Inc	aparelho para controlar posição da língua de um paciente
JP2013509943A (ja)	2009-11-10	2013-03-21	イムセラ・メディカル・インコーポレーテッド	舌下神経を刺激して患者の舌の位置を調節するシステム
US8825164B2 (en)	2010-06-11	2014-09-02	Enteromedics Inc.	Neural modulation devices and methods
WO2015134747A1 (en)	2014-03-06	2015-09-11	Mayo Foundation For Medical Education And Research	Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR748807A (fr) *	1932-03-10	1933-07-10	Gulf Refining Co	Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) *	1969-02-17	1970-10-27	Alza Corp	Medication method
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) *	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) *	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) *	1981-10-01	1990-10-09	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) *	1981-10-01	1992-08-11	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) *	1981-10-01	1991-10-15	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) *	1983-07-14	1986-07-01	Unites States Steel Corporation	Impact modified methyl methacrylate polymer
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4800162A (en) *	1987-04-01	1989-01-24	Sepracor, Inc.	Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) *	1988-04-07	1991-10-15	Sepracor, Inc.	Method for resolution of stereoisomers
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) *	1988-10-13	1988-11-23	Glaxo Group Ltd	Chemical compounds
JPH02188523A (ja) *	1989-01-13	1990-07-24	M S C:Kk	睡眠時無呼吸症治療薬
IT1229203B (it) *	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) *	1989-06-28	1991-12-24	University Of Virginia Alumni Patents Foundation	Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) *	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5356934A (en) *	1990-03-29	1994-10-18	Eli Lilly And Company	Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) *	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
DE69226961T2 (de) *	1991-12-21	1999-04-29	Smithkline Beecham P.L.C., Brentford, Middlesex	Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) *	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) *	1993-05-25	1993-07-14	Glaxo Lab Sa	Compositions
US5407953A (en) *	1994-02-04	1995-04-18	Morgan; Julia A.	Treating apnea/hypopnea/snoring in humans
US5502067A (en) *	1994-02-04	1996-03-26	Morgan; Julia A.	Treating apneahypopnea/snoring in humans
IT1270594B (it) *	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) *	1995-06-13	1997-07-11	Synthelabo	Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CN1196681C (zh) *	1997-07-11	2005-04-13	詹森药业有限公司	(+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途

1999
- 1999-06-10 TR TR2001/03057T patent/TR200103057T2/xx unknown
- 1999-06-10 DE DE69924375T patent/DE69924375T2/de not_active Expired - Fee Related
- 1999-06-10 ES ES99927431T patent/ES2237110T3/es not_active Expired - Lifetime
- 1999-06-10 NZ NZ535135A patent/NZ535135A/en unknown
- 1999-06-10 PT PT99927431T patent/PT1089733E/pt unknown
- 1999-06-10 HK HK02101721.2A patent/HK1040058A1/zh unknown
- 1999-06-10 JP JP2000554444A patent/JP2002518352A/ja active Pending
- 1999-06-10 TR TR2001/03056T patent/TR200103056T2/xx unknown
- 1999-06-10 NZ NZ508824A patent/NZ508824A/en unknown
- 1999-06-10 KR KR1020007014024A patent/KR20010052739A/ko not_active Ceased
- 1999-06-10 TR TR2001/03058T patent/TR200103058T2/xx unknown
- 1999-06-10 CN CN99809565A patent/CN1312717A/zh active Pending
- 1999-06-10 AT AT99927431T patent/ATE291427T1/de not_active IP Right Cessation
- 1999-06-10 TR TR2001/03059T patent/TR200103059T2/xx unknown
- 1999-06-10 CA CA002333666A patent/CA2333666A1/en not_active Abandoned
- 1999-06-10 TR TR2001/03054T patent/TR200103054T2/xx unknown
- 1999-06-10 BR BR9911299-0A patent/BR9911299A/pt not_active IP Right Cessation
- 1999-06-10 NZ NZ526943A patent/NZ526943A/en unknown
- 1999-06-10 IL IL14011899A patent/IL140118A0/xx unknown
- 1999-06-10 KR KR1020067010979A patent/KR20060067986A/ko not_active Ceased
- 1999-06-10 EP EP99927431A patent/EP1089733B1/en not_active Expired - Lifetime
- 1999-06-10 SK SK1905-2000A patent/SK19052000A3/sk unknown
- 1999-06-10 WO PCT/US1999/013099 patent/WO1999065571A2/en not_active Ceased
- 1999-06-10 CZ CZ20004737A patent/CZ20004737A3/cs unknown
- 1999-06-10 PL PL99345275A patent/PL345275A1/xx unknown
- 1999-06-10 SI SI9930764T patent/SI1089733T1/xx unknown
- 1999-06-10 AU AU44333/99A patent/AU4433399A/en not_active Abandoned
- 1999-06-10 TR TR2001/03055T patent/TR200103055T2/xx unknown
- 1999-06-10 HU HU0102203A patent/HUP0102203A3/hu unknown
- 1999-06-10 TR TR2000/03708T patent/TR200003708T2/xx unknown
- 1999-06-10 KR KR1020067003047A patent/KR20060017570A/ko not_active Ceased
- 1999-06-14 US US09/332,196 patent/US6048879A/en not_active Expired - Fee Related
- 1999-06-15 AR ARP990102863A patent/AR019671A1/es unknown
2000
- 2000-02-29 US US09/515,390 patent/US6369079B1/en not_active Expired - Fee Related
- 2000-12-08 IS IS5756A patent/IS5756A/is unknown
- 2000-12-13 NO NO20006357A patent/NO20006357L/no unknown
- 2000-12-27 BG BG105096A patent/BG105096A/xx unknown
2002
- 2002-02-15 US US10/075,617 patent/US6835740B2/en not_active Expired - Fee Related
2004
- 2004-11-30 US US10/998,566 patent/US20050154018A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20010052739A (ko)	2001-06-25
NZ508824A (en)	2003-10-31
KR20060067986A (ko)	2006-06-20
TR200103054T2 (tr)	2002-06-21
NZ535135A (en)	2006-04-28
WO1999065571A2 (en)	1999-12-23
US20050154018A1 (en)	2005-07-14
DE69924375D1 (de)	2005-04-28
KR20060017570A (ko)	2006-02-23
ATE291427T1 (de)	2005-04-15
US20020147220A1 (en)	2002-10-10
TR200103056T2 (tr)	2002-06-21
BR9911299A (pt)	2001-03-13
US6048879A (en)	2000-04-11
TR200103059T2 (tr)	2002-06-21
EP1089733B1 (en)	2005-03-23
CZ20004737A3 (cs)	2001-10-17
HUP0102203A2 (hu)	2001-11-28
EP1089733A2 (en)	2001-04-11
US6369079B1 (en)	2002-04-09
TR200103057T2 (tr)	2002-06-21
NO20006357D0 (no)	2000-12-13
AR019671A1 (es)	2002-03-13
US6835740B2 (en)	2004-12-28
HK1040058A1 (zh)	2002-05-24
PL345275A1 (en)	2001-12-03
HUP0102203A3 (en)	2001-12-28
JP2002518352A (ja)	2002-06-25
BG105096A (en)	2002-02-28
TR200103058T2 (tr)	2002-06-21
DE69924375T2 (de)	2005-08-11
IL140118A0 (en)	2002-02-10
ES2237110T3 (es)	2005-07-16
IS5756A (is)	2000-12-08
NZ526943A (en)	2004-11-26
CA2333666A1 (en)	1999-12-23
TR200103055T2 (tr)	2002-06-21
CN1312717A (zh)	2001-09-12
WO1999065571A3 (en)	2000-04-20
AU4433399A (en)	2000-01-05
NO20006357L (no)	2001-02-13
PT1089733E (pt)	2005-08-31
TR200003708T2 (tr)	2001-06-21
SI1089733T1 (en)	2005-06-30

Publication	Publication Date	Title
US6048879A (en)	2000-04-11	Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride
AU764474B2 (en)	2003-08-21	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
HRP20010075A2 (en)	2002-02-28	Methods and compositions for treating gastro-esophageal reflux disease
AU2003220743B2 (en)	2006-06-15	Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1468685A2 (en)	2004-10-20	Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A2 (en)	2004-10-06	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
MXPA00012364A (en)	2001-12-04	Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
MXPA00012365A (en)	2001-12-04	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders